Involvement of Prolyl Hydroxylase Domain Protein in the Rosiglitazone-Induced Suppression of Osteoblast Differentiation

Involvement of Prolyl Hydroxylase Domain Protein in the Rosiglitazone-Induced Suppression of Osteoblast Differentiation

Rosiglitazone is a well-known anti-diabetic drug that increases insulin sensitivity via peroxisome proliferator-activated receptor γ (PPARγ) activation, but unfortunately it causes bone loss in animals and humans. A previous study showed that prolyl hydroxylase domain protein (PHD) plays a role in r...

Full description

Bibliographic Details
Main Authors: Kang, Ju-Hee, Kwak, Hyun Jeong, Choi, Hye-Eun, Kim, Juyoung, Hong, Sangmee, Kim, Ok-Hee, Oh, Byung Chul, Cheon, Hyae Gyeong
Format: Online
Language:English
Published: Public Library of Science 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587972/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587972/

Similar Items